Clinical Trials Logo

Surgical Wounds clinical trials

View clinical trials related to Surgical Wounds.

Filter by:
  • None
  • Page 1

NCT ID: NCT03286452 Completed - Pressure Ulcer Clinical Trials

The RESPOND Registry

RESPOND
Start date: February 21, 2017
Phase:
Study type: Observational [Patient Registry]

The RESPOND Registry is an observational study to assess the impact of PuraPly™ AM on the management of wounds in real world clinical settings; no experimental intervention is involved.

NCT ID: NCT03070925 Completed - Pressure Ulcers Clinical Trials

Prospective PuraPly™ AM Case Series Study

Start date: November 2016
Phase: N/A
Study type: Observational

The PuraPly AM case series is a prospective, observational study for patients who have received PuraPly AM which consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) and is intended for the management of wounds; no experimental intervention is involved.

NCT ID: NCT02604251 Completed - Surgical Wounds Clinical Trials

Evaluation of the KLOX BioPhotonic WoundGel System in the Treatment of Surgical Wounds

Start date: October 2015
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, prospective, controlled study in patients having bilateral breast reduction. Objectives of the study are to evaluate the safety and efficacy of the KLOX BioPhotonic WoundGel System compared with the ones of Silicone Sheets in the treatment of surgical wounds.

NCT ID: NCT01650571 Completed - Surgical Wounds Clinical Trials

Evaluation of a 'Hand-Held' Fluorescence Digital Imaging Device for Real-Time Advanced Wound Care Monitoring (SMH/UHN)

SMH/UHN
Start date: October 2012
Phase: N/A
Study type: Observational

Currently, standard wound care practice is suboptimal at assessing wound remodeling and bacterial infection in real-time. An alternative and complimentary means of providing real-time imaging of connective tissue re-modeling and bacterial infection may greatly increase the early detection of infection thus leading to rapid therapeutic intervention. Our new device, PRODIGI(TM), images tissue and bacterial autofluorescence (without agents) and may provide this clinically-important capability. In preliminary preclinical testing, the investigators have discovered that when wounds are illuminated by violet/blue light, endogenous collagen in the connective tissue matrix emit a characteristic green fluorescent signal, while most pathogenic bacterial species emit a unique red fluorescence signal due to the production of endogenous porphyrins. Therefore, with autofluorescence imaging, no exogenous contrast agents are needed during imaging, making this approach particularly appealing as a diagnostic imaging method for clinical use. The investigators hypothesize that real-time imaging of tissue autofluorescence signals emanating from endogenous connective tissue (e.g. collagen) and pathogenic bacteria within complex wounds can be used to determine healing status (i.e., collagen re-modeling and wound closure), detect wound bacterial contamination and/or infection that is occult under standard clinical white light evaluation, and guide intervention and wound care.